Suppr超能文献

早期T分期涎腺导管癌:治疗结果及对患者咨询的意义

Early T Stage Salivary Duct Carcinoma: Outcomes and Implications for Patient Counseling.

作者信息

Schmitt Nicole C, Sharma Arun, Gilbert Mark R, Kim Seungwon

机构信息

Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University, Baltimore, Maryland, USA.

Division of Otolaryngology-Head and Neck Surgery, Southern Illinois University, Springfield, Illinois, USA.

出版信息

Otolaryngol Head Neck Surg. 2015 Nov;153(5):795-8. doi: 10.1177/0194599815601659. Epub 2015 Aug 25.

Abstract

Salivary duct carcinoma (SDC) is a rare salivary malignancy that often presents at advanced stage. Outcomes of low T stage patients with SDC have not been previously examined in detail. We queried our institution's cancer database and identified 28 patients with SDC in situ or T1/T2 SDC. A retrospective chart review was performed, followed by comparison of clinicopathologic features with N stage, disease-free survival, and overall survival. Patients tended to be male, in their sixties, with a high incidence of regional metastases, as in prior reports. Five-year disease-free and overall survival were 49%. Median disease-free survival was 3.24 years, and overall survival was 4.65 years. Parotid location, vascular invasion, facial nerve sacrifice, and extracapsular extension were associated with worse survival. This study provides practical information for counseling of patients who undergo surgery for a parotid mass and are found to have this aggressive malignancy.

摘要

涎腺导管癌(SDC)是一种罕见的涎腺恶性肿瘤,通常在晚期出现。此前尚未对低T分期的SDC患者的预后进行详细研究。我们查询了本机构的癌症数据库,确定了28例原位SDC或T1/T2期SDC患者。进行了回顾性病历审查,随后将临床病理特征与N分期、无病生存率和总生存率进行了比较。与既往报道一样,患者多为60多岁的男性,区域转移发生率较高。5年无病生存率和总生存率均为49%。无病生存期中位数为3.24年,总生存期中位数为4.65年。腮腺部位、血管侵犯、面神经牺牲和包膜外扩展与较差的生存率相关。本研究为接受腮腺肿块手术且被发现患有这种侵袭性恶性肿瘤的患者的咨询提供了实用信息。

相似文献

1
Early T Stage Salivary Duct Carcinoma: Outcomes and Implications for Patient Counseling.
Otolaryngol Head Neck Surg. 2015 Nov;153(5):795-8. doi: 10.1177/0194599815601659. Epub 2015 Aug 25.
2
A 20-Year Review of 75 Cases of Salivary Duct Carcinoma.
JAMA Otolaryngol Head Neck Surg. 2016 May 1;142(5):489-95. doi: 10.1001/jamaoto.2015.3930.
3
Parotid salivary duct carcinoma: a single institution's 20-year experience.
Eur Arch Otorhinolaryngol. 2019 Jul;276(7):2031-2038. doi: 10.1007/s00405-019-05454-0. Epub 2019 May 6.
4
Three new cases of salivary duct carcinoma in the palate: a radiologic investigation and review of the literature.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Jun;95(6):752-60. doi: 10.1067/moe.2003.246.
8
Clinicopathological features and treatment outcomes of the rare, salivary duct carcinoma of parotid gland.
J Otolaryngol Head Neck Surg. 2016 May 16;45(1):32. doi: 10.1186/s40463-016-0146-2.
9
Salivary duct carcinoma: A report of 70 FNA cases and review of the literature.
Cancer Cytopathol. 2022 Aug;130(8):595-608. doi: 10.1002/cncy.22568. Epub 2022 Mar 7.
10
Salivary duct carcinomas: clinical and CT and MR imaging features in 20 patients.
Neuroradiology. 2012 Jun;54(6):631-40. doi: 10.1007/s00234-012-1014-z. Epub 2012 Feb 4.

引用本文的文献

1
Surgery Alone without Adjuvant Radiation Therapy for High- or Intermediate-Grade Salivary Gland Cancer.
ORL J Otorhinolaryngol Relat Spec. 2025 Jun 28:1-10. doi: 10.1159/000547198.
2
Clinicopathologic Factors and Their Association with Outcomes of Salivary Duct Carcinoma: A Multicenter Experience.
Adv Radiat Oncol. 2023 Mar 1;8(4):101204. doi: 10.1016/j.adro.2023.101204. eCollection 2023 Jul-Aug.
4
VDR in salivary gland homeostasis and cancer.
J Steroid Biochem Mol Biol. 2020 May;199:105600. doi: 10.1016/j.jsbmb.2020.105600. Epub 2020 Jan 17.
5
Intensity Modulated Radiotherapy (IMRT) With Carbon Ion Boost in the Multimodal Treatment of Salivary Duct Carcinoma.
Front Oncol. 2019 Dec 20;9:1420. doi: 10.3389/fonc.2019.01420. eCollection 2019.
6
Extracapsular extension is not a significant prognostic indicator in non-squamous cancers of the major salivary glands.
Cancers Head Neck. 2018 Jul 3;3:5. doi: 10.1186/s41199-018-0032-x. eCollection 2018.
8
Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy.
Oral Oncol. 2017 Nov;74:40-48. doi: 10.1016/j.oraloncology.2017.09.008. Epub 2017 Sep 21.

本文引用的文献

4
Salivary duct carcinoma: what is already known, and can we improve survival?
J Laryngol Otol. 2012 Jul;126 Suppl 2:S2-7. doi: 10.1017/S0022215112000412. Epub 2012 Apr 12.
5
Management and outcome of salivary duct carcinoma in major salivary glands.
Eur Arch Otorhinolaryngol. 2013 Jan;270(1):281-5. doi: 10.1007/s00405-012-1997-4. Epub 2012 Mar 22.
6
Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options.
J Clin Oncol. 2011 Jun 1;29(16):e473-6. doi: 10.1200/JCO.2010.32.8351. Epub 2011 Mar 21.
7
Biological therapy of salivary duct carcinoma.
J Laryngol Otol. 2009 Feb;123(2):250-2. doi: 10.1017/S0022215108002314. Epub 2008 Apr 11.
10
Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases.
Cancer. 2005 Jun 15;103(12):2526-33. doi: 10.1002/cncr.21116.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验